Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012

JACC. Basic to Translational Science
Thomas J HwangAaron S Kesselheim

Abstract

Cardiovascular disease remains a leading cause of death, but stakeholders have recently raised concerns about the pace of innovation and investment in developing new therapeutics. Here, the authors characterized temporal trends in cardiovascular research and development over the past 2 decades and the likelihood of successful completion of pre-approval clinical trials. The authors also evaluated the reasons for discontinuation, novelty, and rates of trial results publication for cardiovascular therapies in late-stage development. Between 1990 and 2012, the number of new cardiovascular drugs entering clinical trials declined across all stages of development (p < 0.001 for linear trends). There was no evidence for a difference in probability of successful progression to the next stage of development between cardiovascular and noncardiovascular drugs. Small and medium-sized companies sponsored 43%, 38%, and 31% of new Phase 1, Phase 2, and Phase 3 trials, respectively. Roughly one-half of the drugs in Phase 3 trials were categorized as targeting a novel biological pathway. The number of cardiovascular trials sponsored by small and medium-sized companies and the number of novel drugs entering Phase 3 trials increased over time. Mos...Continue Reading

References

Jan 29, 2003·Proceedings of the National Academy of Sciences of the United States of America·Nabil G SeidahMichel Chretien
May 6, 2003·Nature Genetics·Marianne AbifadelCatherine Boileau
Jul 23, 2003·Circulation·Eric J TopolUNKNOWN Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators
Jun 11, 2004·The New England Journal of Medicine·K Srinath Reddy
Apr 5, 2005·Proceedings of the National Academy of Sciences of the United States of America·Shirya RashidJay D Horton
Mar 9, 2006·Health Affairs·Christopher P Adams, Van V Brantner
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Mar 28, 2008·The New England Journal of Medicine·Daniel CarpenterJerry Avorn
Aug 13, 2008·Proceedings of the National Academy of Sciences of the United States of America·Maria Frank-KamenetskyKevin Fitzgerald
Mar 20, 2009·The New England Journal of Medicine·Alan M Garber
Jun 2, 2011·Nature Reviews. Drug Discovery·Fabio PammolliMassimo Riccaboni
Mar 23, 2012·The New England Journal of Medicine·Evan A SteinGary D Swergold
Apr 13, 2013·Nature·Stephen S Hall
Nov 20, 2013·JAMA : the Journal of the American Medical Association·Stephen J NichollsUNKNOWN VISTA-16 Investigators
Feb 1, 2014·Nature Reviews. Drug Discovery·Helene LinckerHans-Georg Eichler
May 31, 2014·Science·Thomas J HwangAaron S Kesselheim
Jun 26, 2014·The New England Journal of Medicine·Aaron S Kesselheim, Jonathan J Darrow
Jul 19, 2014·Nature Reviews. Drug Discovery·Jörg EderChristian Wiesmann
Aug 2, 2014·Journal of the American College of Cardiology·Valentin Fuster
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Nov 20, 2014·JAMA : the Journal of the American Medical Association·Kathy L Hudson, Francis S Collins
Apr 18, 2015·Journal of the American College of Cardiology·Christopher B FordyceRobert M Califf
Sep 25, 2015·BMJ : British Medical Journal·Aaron S KesselheimJonathan J Darrow
Sep 29, 2015·Vaccine·Erin CrosseyAlan T Remaley
Oct 8, 2015·The New England Journal of Medicine·Brendan M EverettWilliam R Hiatt
Nov 19, 2015·The Canadian Journal of Cardiology·David D Waters, Katherine Hsin-Yu Chau
Nov 21, 2015·Nature Reviews. Drug Discovery·Aaron S KesselheimJessica M Franklin

❮ Previous
Next ❯

Citations

Apr 20, 2019·Clinical Pharmacology and Therapeutics·Oluseyi AdeniyiMichael Pacanowski
Aug 28, 2017·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Javaid IqbalBernard J Gersh
May 29, 2018·Current Cardiology Reports·Arne A N BruyneelMark Mercola
Apr 14, 2021·European Heart Journal·Gemma A FigtreeFaiez Zannad

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass

Software Mentioned

Stata

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.